Search results
Benjamin F. Edwards & Company Inc. Raises Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 6 days agoBenjamin F. Edwards & Company Inc. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 17.2% during the 4th quarter, according to its most...Securities ...
Smart Money Is Betting Big In MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 2 days agoModerna, we move to examine the company in more detail. This includes an assessment of its current market status and performance. Present Market Standing of Moderna ...
Company News For May 13, 2024
Zacks via Yahoo Finance· 4 days agoNovavax, Inc. (NVAX) shares surged 98.7% after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu vaccine. ...
Jim Cramer: This Industrial Company Is ‘Absolutely Terrific’, Recommends Buying Modine Manufacturing...
Benzinga· 2 days agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna
Post-pandemic problems: These stocks are still down more than 50 percent from their Covid highs
Bankrate via AOL· 2 days agoIts shares traded as low as $3.55 in December 2022. Covid high stock price: $376.83 Current stock...
Bull Market and Beyond: 2 Stocks Just Waiting to Soar | The Motley Fool
The Motley Fool· 4 days agoLet's consider two such stocks: Moderna (MRNA 7.13%) and DexCom (DXCM -1.65%). Moderna is one of the...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 21 hours agoIn the past six months, shares of MRNA have rallied 69.04%. (See the last biotech stock roundup...
These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital,...
Barrons.com· 7 days agoNovavax stock surged after the vaccine maker signs a $1.2 billion licensing deal with France’s...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 4 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345.
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Investor's Business Daily· 3 days agoNovavax will also receive tiered royalties on sales. Sanofi also made a $70 million investment in...